Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group
Por:
Fernández-Díaz, N, Mateos-González, M, Pertejo-Fernández, A, Cacho-Lavín, JD, Juan-Fita, MJ, Chirivella-González, I, Arruti-Ibarbia, M, Fernández-Calvo, O, Fernández-Núñez, N, Méndez-Vidal, MJ, Lázaro-Quintela, M, Molina-Díaz, A, Del Pozo-Alonso, N, Etxaniz-Ulazia, O, García-Acuña, SM, Betancor, YZ, Azueta-Etxebarria, A, Calatrava-Fons, A, Lombardía-Rodríguez, H, Alarcon-Molero, L, Etxegarai-Ganboa, L, Anton-Cameselle, A, Bello-Giz, JA, Neira-De Paz, CM, Cabaleiro, T, González-Serrano, T, Ortiz-Rey, JA, Sacristán-Lista, F, García-Rubín, S, Ortega, E, Carrato-Moñino, C, Aguín-Losada, S, Leon-Mateos, L, García-González, J, Pinto-Marín, A, Duran, I, Lopez-Lopez, R, Anido-Herranz, U and Ruiz-Bañobre, J
Publicada:
28 nov 2025
Ahead of Print:
28 nov 2025
Resumen:
Background The efficacy of nivolumab for advanced renal cell carcinoma (aRCC) has been evaluated in real-world evidence (RWE) studies across several European countries, yet data from Spain have been lacking. Patients and methods We conducted a multicenter, retrospective study of 222 previously treated aRCC patients to assess the efficacy of nivolumab and the influence of pre-treatment factors on clinical outcomes across 13 Spanish centers. Eligible patients had received at least one dose of nivolumab in routine clinical practice. Demographic, clinical, and laboratory data were extracted from electronic records. Efficacy endpoints were overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and overall response rate (ORR). Survival estimates were calculated by the Kaplan-Meier method, and groups were compared with the log-rank test. The Cox proportional hazards regression model was used to evaluate factors independently associated with OS. Factors associated with disease control (DC) and response were tested with logistic regression in univariable and multivariable analyses. Comparisons between patient and disease characteristics were carried out using Fisher's exact test. All P values were two-sided, and those < 0.05 were considered statistically significant. Results were contextualized with key clinical experiences involving nivolumab monotherapy in aRCC. Results With a median follow-up of 14.6 months, median overall survival (OS) was 18.1 months (95% confidence interval [CI], 14.2-23.7 months), and median progression-free survival (PFS) was 4.96 months (95% CI, 3.98-7.13). The disease control rate was 51% (95% CI, 45-58%), and the objective response rate was 23% (95% CI, 18-30%). Poor International Metastatic RCC Database Consortium (IMDC) risk score was independently associated with shorter OS, while prior nephrectomy predicted improved OS. Poor IMDC risk and >= 3 metastatic sites were independently associated with shorter PFS; >= 3 metastatic sites also correlated with reduced disease control. Conclusion Consistent with previous clinical trials and RWE studies, our findings reinforce the efficacy of nivolumab in routine clinical practice for an unselected cohort of previously treated aRCC patients in Spain.
Filiaciones:
Fernández-Díaz, N:
Univ Clin Hosp Santiago de Compostela SERGAS, Dept Med Oncol, Santiago De Compostela, Spain
Hlth Res Inst Santiago Compostela IDIS, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain
Univ Santiago De Compostela USC, Santiago De Compostela, Spain
Mateos-González, M:
Univ Clin Hosp Santiago de Compostela SERGAS, Dept Med Oncol, Santiago De Compostela, Spain
Hlth Res Inst Santiago Compostela IDIS, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain
Pertejo-Fernández, A:
Hosp Univ La Paz Idipaz, Dept Med Oncol, Madrid, Spain
Cacho-Lavín, JD:
Hosp Univ Marques Valdecilla, Dept Med Oncol, IDIVAL, Santander, Spain
Juan-Fita, MJ:
Fdn Inst Valenciano Oncol IVO, Dept Med Oncol, Valencia, Spain
Chirivella-González, I:
Univ Valencia, INCLIVA Biomed Res Inst, Dept Med Oncol, Valencia, Spain
Arruti-Ibarbia, M:
Hosp Galdakao Usansolo, Dept Med Oncol, Bizkaia, Spain
Fernández-Calvo, O:
Complejo Hosp Univ Ourense, Dept Med Oncol, Orense, Spain
Fernández-Núñez, N:
Hosp Univ Lucus Augusti, Dept Med Oncol, Lugo, Spain
Méndez-Vidal, MJ:
Hosp Univ Reina Sofia, Maimonides Inst Biomed Res Cordoba IMIBIC, Dept Med Oncol, Cordoba, Spain
Lázaro-Quintela, M:
Complejo Hosp Univ Vigo, Dept Med Oncol, Vigo, Spain
Molina-Díaz, A:
Complejo Hosp Univ Coruna, Dept Med Oncol, La Coruna, Spain
Del Pozo-Alonso, N:
Hosp Univ Vinalopo, Dept Med Oncol, Elche, Alicante, Spain
Etxaniz-Ulazia, O:
Hosp Germans Trias I Pujol, Catalan Inst Oncol ICO, Dept Med Oncol, Badalona, Barcelona, Spain
García-Acuña, SM:
Univ Clin Hosp Santiago de Compostela SERGAS, Univ Santiago de Compostela USC, Dept Pathol, Santiago De Compostela, Spain
Betancor, YZ:
Hlth Res Inst Santiago Compostela IDIS, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain
Univ Santiago De Compostela USC, Santiago De Compostela, Spain
Univ Santiago de Compostela USC, Ctr Res Mol Med & Chron Dis CiMUS, Genomes & Dis, Santiago De Compostela, Spain
Azueta-Etxebarria, A:
Hosp Univ Marques Valdecilla, Dept Pathol, IDIVAL, Santander, Spain
Basurto Univ Hosp, Biocruces Bizkaia Hlth Res Inst, Translat Prostate Canc Res Lab, CIC bioGUNE Basurto,Dept Pathol, Bilbao, Spain
Calatrava-Fons, A:
Fdn Inst Valenciano Oncol IVO, Dept Pathol, Valencia, Spain
Lombardía-Rodríguez, H:
Hlth Res Inst Santiago Compostela IDIS, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain
Univ Santiago De Compostela USC, Santiago De Compostela, Spain
Alarcon-Molero, L:
Hosp Clin Univ Valencia, Dept Pathol, Valencia, Spain
Gen Hosp Valdepenas, Dept Pathol, Ciudad Real, Spain
Etxegarai-Ganboa, L:
Hosp Galdakao Usansolo, Dept Pathol, Bizkaia, Spain
Anton-Cameselle, A:
Hlth Res Inst Santiago Compostela IDIS, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain
Univ Santiago De Compostela USC, Santiago De Compostela, Spain
Bello-Giz, JA:
Complejo Hosp Univ Ourense, Dept Pathol, Orense, Spain
Neira-De Paz, CM:
Hosp Univ Lucus Augusti, Dept Pathol, Lugo, Spain
Cabaleiro, T:
Univ Clin Hosp Santiago de Compostela, Fdn Publ Galega Inst Invest Sanitaria Santiago Com, Santiago De Compostela, Spain
González-Serrano, T:
Univ Cordoba, Hosp Reina Sofia, Maimonides Inst Biomed Res IMIB, Cordoba, Spain
Ortiz-Rey, JA:
Complejo Hosp Univ Vigo, Dept Pathol, Vigo, Spain
Sacristán-Lista, F:
Complejo Hosp Univ Coruna, Dept Pathol, La Coruna, Spain
García-Rubín, S:
Hlth Res Inst Santiago Compostela IDIS, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain
Ortega, E:
Hosp Univ Vinalopo, Dept Pathol, Elche, Alicante, Spain
:
Hosp Germans Trias I Pujol, Dept Pathol, Badalona, Barcelona, Spain
Aguín-Losada, S:
Univ Clin Hosp Santiago de Compostela SERGAS, Dept Med Oncol, Santiago De Compostela, Spain
Hlth Res Inst Santiago Compostela IDIS, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain
Leon-Mateos, L:
Univ Clin Hosp Santiago de Compostela SERGAS, Dept Med Oncol, Santiago De Compostela, Spain
Hlth Res Inst Santiago Compostela IDIS, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain
Univ Santiago De Compostela USC, Santiago De Compostela, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
García-González, J:
Univ Clin Hosp Santiago de Compostela SERGAS, Dept Med Oncol, Santiago De Compostela, Spain
Hlth Res Inst Santiago Compostela IDIS, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Pinto-Marín, A:
Hosp Univ La Paz Idipaz, Dept Med Oncol, Madrid, Spain
Duran, I:
Hosp Univ Marques Valdecilla, Dept Med Oncol, IDIVAL, Santander, Spain
Lopez-Lopez, R:
Univ Clin Hosp Santiago de Compostela SERGAS, Dept Med Oncol, Santiago De Compostela, Spain
Hlth Res Inst Santiago Compostela IDIS, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain
Univ Santiago De Compostela USC, Santiago De Compostela, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Anido-Herranz, U:
Univ Clin Hosp Santiago de Compostela SERGAS, Dept Med Oncol, Santiago De Compostela, Spain
Hlth Res Inst Santiago Compostela IDIS, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain
Ruiz-Bañobre, J:
Univ Clin Hosp Santiago de Compostela SERGAS, Dept Med Oncol, Santiago De Compostela, Spain
Hlth Res Inst Santiago Compostela IDIS, Translat Med Oncol Grp ONCOMET, Santiago De Compostela, Spain
Univ Santiago De Compostela USC, Santiago De Compostela, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Green Submitted, gold
|